• 1
    Sisson DD, Thomas WP. Myocardial diseases. In: EttingerSJ, ed. Textbook of Veterinary Internal Medicine. Diseases of the Dog and Cat, 4th ed. Philadelphia, PA: WB Saunders; 1995:9951032.
  • 2
    Buchanan JW. Causes and prevalence of cardiovascular disease. In: KirkRW, BonaguraJD, eds. Current Veterinary Therapy XI. Philadelphia, PA: WB Saunders; 1992:647654.
  • 3
    Calvert CA, Meurs KM. CVT Update: Doberman pinscher occult cardiomyopathy. In: BonaguraJD, ed. Current Veterinary Therapy XIII. Philadelphia, PA: WB Saunders; 2000:756760.
  • 4
    O'Grady MR. DCM in Doberman Pinschers: Lessons learned in the first decade of study. Proceedings 20th ACVIM Forum 2002;114115.
  • 5
    O'Grady MR, O'Sullivan ML. Dilated cardiomyopathy: An update. Vet Clin Small Anim 2004;34:11871207.
  • 6
    Calvert CA, Jacobs GJ, Pickus CW, et al. Signalment, survival, and prognostic factors in Doberman Pinschers with end-stage cardiomyopathy. J Vet Int Med 1997;11:323.
  • 7
    The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the Cooperative Veterinary Enalapril Study Group. J Vet Int Med 1995;9:243252.
  • 8
    The IMPROVE Study Group. Acute and short-term hemodynamics, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: Results of the Invasive Multicenter Prospective Veterinary Evaluation of Enalapril Study. J Vet Int Med 1995;9:234242.
  • 9
    Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc 1998;213:15731577.
  • 10
    The BENCH (Benazepril Hydrochloride in Canine Heart Disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardio 1999;1:718.
  • 11
    Van Meel JCA, Dierden W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharm 1989;14 (Suppl 2):S1S6.
  • 12
    Fujino K, Sperelakis N, Solaro RJ. Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: Comparison with milrinone. Circ Res 1988;63:911922.
  • 13
    Pouleur H, Hanet C, Schroder E, et al. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure. J Cardiovasc Pharmacol 1989;14 (Suppl 2):S18S22.
  • 14
    Ravens U, Himmel HM, Fluss M, et al. Phosphodiesterase inhibition and Ca2+ sensitization. Mol Cell Biochem 1996;157:245249.
  • 15
    Sato N, Asai K, Okumura S, et al. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Physiol 1999;276:H1699H1705.
  • 16
    Hagemeijer F. Calcium sensitization with pimobendan; pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J 1993;14:551566.
  • 17
    Verdouw PD, Hartog JM, Duncker DJ, et al. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986;126:2130.
  • 18
    Sasaki T, Kubo T, Komamura K, Nishikimi T. Effect of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. J Cardio 1999;33:317325.
  • 19
    Erlemeier HH, Kupper W, Bleifield W. Comparison of hormonal and hemodynamic changes after long-term therapy with pimobendan or enalapril—A double-blind randomised study. Eur Heart J 1991;12:889899.
  • 20
    Baumann G, Ningel K, Permanetter B. Cardiovascular profile of UD-CG 115BS—Pimobendan and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 1989;13:730738.
  • 21
    Asanoi H, Ishizaka S, Kameyama T, et al. Disparate inotropic and lusitropic response to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 1994;23:268274.
  • 22
    Iwasaki A, Matsumori A, Yamada T, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardio 1999;33:14001407.
  • 23
    Fuentes VL, Corcoran B, French A, Schober KE, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Int Med 2002;16:255261.
  • 24
    Lombard CW. Pimobendan in congestive heart failure. Proceedings 21st ACVIM Forum 2003;104.
  • 25
    Lombard CW. Pimobendan in mitral regurgitation versus dilated cardiomyopathy. Proceedings 22nd ACVIM Forum 2004;9798.
  • 26
    The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild-to-moderate heart failure—The effects of pimobendan on chronic heart failure study. Circ J 2002;66:149157.
  • 27
    Smith PJ, French AT, Van Israel N, et al. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005;46:121130.
  • 28
    Lombard CW, Jones O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249261.
  • 29
    Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194199.
  • 30
    Givertz MM, Colucci WS, Braunwald E. Clinical aspects of heart failure; pulmonary edema, high-output failure. In: ZipesDP, LibbyP, BonowRO, BraunwaldE, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed. Philadelphia, PA: Elsevier Saunders; 2005:551555.
  • 31
    Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med 1991;325:14681475.
  • 32
    Lubsen J, Just H, Hjalmarsson AC, et al. Efficacy of pimobendan on exercise capacity in patients with heart failure: Main results from the pimobendan in congestive heart failure (PICO) trial. Heart 1996;76:223231.
  • 33
    Bradburn MJ, Clark TG, Love SB, Altman DG. Survival Analysis Part III: Multivariate data analysis—Choosing a model and assessing its adequacy and fit. Br J Cancer 2003;89:606611.